Stratos Wealth Advisors
CADL icon

Stratos Wealth Advisors’s Candel Therapeutics CADL Stock Holding History

Stratos Wealth Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$566K Buy
54,250
+38,250
+239% +$424K 0.03% 388
2026
Q2 		$165K Sell
16,000
-9,908
-38% -$74.8K 0.01% 622
2026
Q1 		$127K Buy
25,908
+2,908
+13% +$15.8K 0.01% 596
2025
Q4 		$130K Hold
23,000
– – 0.01% 637
2025
Q3 		$117K Hold
23,000
– – 0.01% 662
2025
Q2 		$116K Hold
23,000
– – 0.01% 651
2025
Q1 		$130K Buy
+23,000
New +$188K 0.01% 642

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Stratos Wealth Advisors's CADL Position: Q3 2026 in Review

Stratos Wealth Advisors increased its Candel Therapeutics (CADL) stake by 239% in Q3 2026, buying an estimated $424K and bringing the position to 54,250 shares worth $566K. The position accounts for 0.03% of the portfolio, ranked #388.

Stratos Wealth Advisors first reported a position in CADL in Q1 2025 and has held it in 7 quarters since. 106 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Stratos Wealth Advisors held 54,250 shares of Candel Therapeutics worth $566K as of Q3 2026.
  • Stratos Wealth Advisors bought 38,250 Candel Therapeutics shares in Q3 2026, an estimated $424K.
  • Candel Therapeutics made up 0.03% of Stratos Wealth Advisors's portfolio in Q3 2026, its #388 holding.
  • Stratos Wealth Advisors first reported a position in Candel Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • 106 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Stratos Wealth Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.